Fangsheng Pharmaceutical (603998.SH): Shuangzao Anshen Granules Receives Drug Clinical Trial Approval

Zhitong Finance APP news, FangSheng Pharmaceutical (603998.SH) issued an announcement that on October 30, 2026, the company's traditional Chinese medicine innovative drug research and development project, Shuangzao Anshen Granules, received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration. Shuangzao Anshen Granules is a clinically effective empirical formula developed based on years of clinical diagnosis and treatment practice, used for the treatment of insomnia (syndrome of yin deficiency of liver and kidney). The whole formula takes tonifying and benefiting the liver and kidney, nourishing blood and calming the mind as its core, and is used for the treatment of irritability and sleeplessness, frequent dreaming and easy awakening, palpitations and restlessness, soreness and weakness of the waist and knees, dizziness, tinnitus, and forgetfulness caused by insomnia (syndrome of yin deficiency of liver and kidney).